Xylinas, E. and Cha, E. K. and Sun, M. and Rink, M. and Trinh, Q-D and Novara, G. and Green, D. A. and Pycha, A. and Fradet, Y. and Daneshmand, S. and Svatek, R. S. and Fritsche, H-M and Kassouf, W. and Scherr, D. S. and Faison, T. and Crivelli, J. J. and Tagawa, S. T. and Zerbib, M. and Karakiewicz, P. I. and Shariat, S. F. (2012) Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. BRITISH JOURNAL OF CANCER, 107 (11). pp. 1826-1832. ISSN 0007-0920, 1532-1827
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: In pT1-T3N0 urothelial carcinoma of the bladder (UCB) patients, multi-modal therapy is inconsistently recommended. The aim of the study was to develop a prognostic tool to help decision-making regarding adjuvant therapy. METHODS: We included 2145 patients with pT1-3N0 UCB after radical cystectomy (RC), naive of neoadjuvant or adjuvant therapy. The cohort was randomly split into development cohort based on the US patients (n = 1067) and validation cohort based on the Europe patients (n = 1078). Predictive accuracy was quantified using the concordance index. RESULTS: With a median follow-up of 45 months, 5-year recurrence-free and cancer-specific survival estimates were 68% and 73%, respectively. pT-stage, ge, lymphovascular invasion, and positive margin were significantly associated with both disease recurrence and cancer-specific mortality (P-values <= 0.005). The accuracies of the multivariable models at 2, 5, and 7 years for predicting disease recurrence were 67.4%, 65%, and 64.4%, respectively. Accuracies at 2, 5, and 7 years for predicting cancer-specific mortality were 69.3%, 66.4%, and 65.5%, respectively. We developed competing-risk, conditional probability nomograms. External validation revealed minor overestimation. CONCLUSION: Despite RC, a significant number of patients with pT1-3N0 UCB experience disease recurrence and ultimately die of UCB. We developed and externally validated competing-risk, conditional probability post-RC nomograms for prediction of disease recurrence and cancer-specific mortality. British Journal of Cancer (2012) 107, 1826-1832. doi:10.1038/bjc.2012.464 www.bjcancer.com (C) 2012 Cancer Research UK
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TRANSITIONAL-CELL CARCINOMA; INVASIVE BLADDER-CANCER; PROSTATE-CANCER; PREOPERATIVE NOMOGRAM; UROTHELIAL CARCINOMA; EXTERNAL VALIDATION; DISEASE RECURRENCE; PREDICTION; SURVIVAL; OUTCOMES; bladder cancer; radical cystectomy; T1-3 N0; prediction; nomogram; chemotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 May 2020 07:45 |
| Last Modified: | 04 May 2020 07:45 |
| URI: | https://pred.uni-regensburg.de/id/eprint/17770 |
Actions (login required)
 |
View Item |
